Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)

Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association; Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association; Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association

doi:10.19401/j.cnki.1007-3639.2024.01.008

您当前的位置：

首页 >

文章列表页 >

Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)

Guideline and Concensus | 更新时间：2025-12-31

- Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)
- China Oncology Vol. 34, Issue 1, Pages: 104-134(2024)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.01.008
  CLC： R730.53
- Received：10 October 2023，
  
  Revised：2023-12-28，
  
  Published：30 January 2024
- 稿件说明：
移动端阅览
Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association, Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association, Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association. Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)[J]. China Oncology, 2024, 34(1): 104-134.
DOI：

Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association, Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association, Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association. Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)[J]. China Oncology, 2024, 34(1): 104-134. DOI： 10.19401/j.cnki.1007-3639.2024.01.008.

摘要

恶性肿瘤患者在接受化疗、放疗、靶向治疗及免疫治疗等抗肿瘤治疗时都可能引发恶心呕吐。化疗所致恶心呕吐（chemotherapy-induced nausea and vomiting，CINV）是最为常见也是目前研究最为深入的不良反应；放疗所致恶心呕吐（radiation-induced nausea and vomiting，RINV）、靶向治疗及免疫治疗所致恶心呕吐（targeted therapy and immunotherapy-induced nausea and vomiting，TIINV）也越来越受到关注。本专家组在《化疗所致恶心呕吐全程管理上海专家共识（2018年版）》的基础上，根据近年来抗肿瘤治疗所致恶心呕吐（antineoplastic-induced nausea and vomiting，AINV）领域的循证医学新证据，结合上海一线肿瘤治疗专家的实际临床经验，最终形成《抗肿瘤治疗所致恶心呕吐全程管理上海专家共识（2024年版）》，以便进一步在上海地区积极、合理、规范、全程地预防和处理AINV，保障患者的治疗强度和医疗安全。

Abstract

Nausea and vomiting are common adverse reactions in tumor patients during anti-tumor therapy such as chemotherapy

radiotherapy

targeted therapy and immunotherapy. Although chemotherapy-induced nausea and vomiting (CINV) is the most common and the most intensively studied adverse event

radiation-induced nausea and vomiting (RINV)

targeted therapy and immunotherapy-induced nausea and vomiting (TIINV) have also attracted more and more attention. Based on “Shanghai expert consensus on whole-process management of chemotherapy-induced nausea and vomiting (2018 edition)”

as well as new medical evidence of antineoplastic-induced nausea and vomiting (AINV) and experience of Shanghai experts in this field

the expert group finally developed “Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)”. This consensus will guide doctors in Shanghai to standardize the whole-process management of AINV

and to ensure the treatment intensity and medical safety of patients.

关键词

Keywords

references

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology: antiemesis [EB/OL ] 2024 , Version 1. [ 2023-11-15 ] . https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.

AAPRO M , SCOTTÉ F , ESCOBAR Y , et al . Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data [J ] . Oncologist , 2021 , 26 ( 6 ): e1073 - e1082 . DOI: 10.1002/onco.13716 http://doi.org/10.1002/onco.13716 https://academic.oup.com/oncolo/article/26/6/e1073/6520983 https://academic.oup.com/oncolo/article/26/6/e1073/6520983

徐永华 , 周佳琦 , 周莎莎 , 等 . 化疗止吐方案的指南依从性分析 [J ] . 中国药业 , 2021 , 30 ( 24 ): 125 - 127 .

XU Y H , ZHOU J Q , ZHOU S S , et al . Adherence analysis of the antiemetic guidelines for chemotherapy-induced nausea and vomiting [J ] . China Pharm , 2021 , 30 ( 24 ): 125 - 127 .

曾铖 , 金奕滋 , 李婷 , 等 . 上海市癌症患者化疗所致恶心呕吐的横断面研究 [J ] . 中国癌症杂志 , 2023 , 33 ( 11 ): 1009 - 1017 . DOI: 10.19401/j.cnki.1007-3639.2023.11.006 http://doi.org/10.19401/j.cnki.1007-3639.2023.11.006

ZENG C , JIN Y Z , LI T , et al . Chemotherapy-induced nausea and vomiting among cancer patients in Shanghai: a cross-sectional study [J ] . China Oncol , 2023 , 33 ( 11 ): 1009 - 1017 .

FEYER P , JAHN F , JORDAN K . Prophylactic management of radiation-induced nausea and vomiting [J ] . Biomed Res Int , 2015 , 2015 : 893013 .

ALDEN-BENNETT V , BALL B , NIGHTINGALE H , et al . Radiation-induced nausea and vomiting: a clinical audit of prophylactic antiemetic use [J ] . J Radiother Pract , 2022 , 21 ( 4 ): 462 - 465 . DOI: 10.1017/S1460396921000133 http://doi.org/10.1017/S1460396921000133 https://www.cambridge.org/core/product/identifier/S1460396921000133/type/journal_article https://www.cambridge.org/core/product/identifier/S1460396921000133/type/journal_article

上海市抗癌协会癌症康复与姑息专业委员会 . 化疗所致恶心呕吐全程管理上海专家共识(2018年版) [J ] . 中国癌症杂志 , 2018 , 28 ( 12 ): 946 - 960 . DOI: 10.19401/j.cnki.1007-3639.2018.12.011 http://doi.org/10.19401/j.cnki.1007-3639.2018.12.011

Cancer Rehabilitation and Palliative Care Committee of Shanghai Anti-Cancer Association . Shanghai Consensus Guidelines for the Management of chemotherapy-induced nausea and vomiting (2018 edition) [J ] . Chin Oncol , 2018 , 28 ( 11 ): 946 - 960 .

SINGH P , YOON S S , KUO B . Nausea: a review of pathophysiology and therapeutics [J ] . Therap Adv Gastroenterol , 2016 , 9 ( 1 ): 98 - 112 . DOI: 10.1177/1756283X15618131 http://doi.org/10.1177/1756283X15618131

DENNIS K , NGUYEN J , PRESUTTI R , et al . Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases [J ] . Support Care Cancer , 2012 , 20 ( 8 ): 1673 - 1678 . DOI: 10.1007/s00520-011-1258-x http://doi.org/10.1007/s00520-011-1258-x

HESKETH P J , KRIS M G , BASCH E , et al . Antiemetics: ASCO guideline update [J ] . J Clin Oncol , 2020 , 38 ( 24 ): 2782 - 2797 . DOI: 10.1200/JCO.20.01296 http://doi.org/10.1200/JCO.20.01296

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会(CSCO)抗肿瘤治疗相关恶心呕吐预防和治疗指南(2019.V1.0) [M ] . 北京 : 人民卫生出版社 , 2019 .

Guidelines Working Committee of Chinese Society of Clinical Oncology . Guidelines of Chinese Society of Clinical Oncology (CSCO) prevention & treatment of nausea and vomiting caused (2019.V1.0) [M ] . Beijing : People’s Health Publishing House , 2019 .

HASHIMOTO H , ABE M , TOKUYAMA O , et al . Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 2 ): 242 - 249 . DOI: S1470-2045(19)30678-3 http://doi.org/S1470-2045(19)30678-3

YEO W , LAU T K , LI L , et al . A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients [J ] . Breast , 2020 , 50 : 30 - 38 . DOI: S0960-9776(20)30006-0 http://doi.org/S0960-9776(20)30006-0

WANG D Y , CHEN Y , ZHANG Y , et al . The balance between the effectiveness and safety for chemotherapy-induced nausea and vomiting of different doses of olanzapine (10 mg versus 5 mg): a systematic review and meta-analysis [J ] . Front Oncol , 2021 , 11 : 705866 . DOI: 10.3389/fonc.2021.705866 http://doi.org/10.3389/fonc.2021.705866 https://www.frontiersin.org/articles/10.3389/fonc.2021.705866/full https://www.frontiersin.org/articles/10.3389/fonc.2021.705866/full

CHOW R , NAVARI R M , TERRY B , et al . Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis [J ] . Support Care Cancer , 2022 , 30 ( 2 ): 1015 - 1018 . DOI: 10.1007/s00520-021-06606-x http://doi.org/10.1007/s00520-021-06606-x

JYOTI BAJPAI , KAPU V , RATH S , et al . A randomized, open-label phase Ⅲ trial evaluating low-dose vs standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in solid tumors (OLAnzaPiNE) [C ] . SABCS , 2023 : RF01 - 08 .

CAO J , WANG B Y , WANG Z H , et al . Efficacy of mirtazapine in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: an open-label, randomized, multicenter phase Ⅲ trial [J ] . J Clin Oncol , 2018 , 36 ( 15_suppl ): 1078 . DOI: 10.1016/S0959-8049(00)00059-9 http://doi.org/10.1016/S0959-8049(00)00059-9 https://linkinghub.elsevier.com/retrieve/pii/S0959804900000599 https://linkinghub.elsevier.com/retrieve/pii/S0959804900000599

ZHANG L Y , QU X J , TENG Y E , et al . Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: a randomized, multicenter, double-blind, placebo-controlled phase Ⅲ trial (CLOG1302 study) [J ] . J Clin Oncol , 2017 , 35 ( 31 ): 3558 - 3565 . DOI: 10.1200/JCO.2017.72.2538 http://doi.org/10.1200/JCO.2017.72.2538 https://ascopubs.org/doi/10.1200/JCO.2017.72.2538 https://ascopubs.org/doi/10.1200/JCO.2017.72.2538

IOROI T , FURUKAWA J , KUME M , et al . Phase Ⅱ study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy [J ] . Support Care Cancer , 2018 , 26 ( 5 ): 1419 - 1423 .

RENZO N D , MUSSO M , SCIMÈ R , et al . Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase Ⅱa, multicenter study [J ] . Bone Marrow Transplant , 2020 , 55 ( 11 ): 2114 - 2120 . DOI: 10.1038/s41409-020-0909-2 http://doi.org/10.1038/s41409-020-0909-2

ZHAO Y Y , YANG Y P , GAO F F , et al . A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study) [J ] . EClinicalMedicine , 2022 , 55 : 101771 . DOI: 10.1016/j.eclinm.2022.101771 http://doi.org/10.1016/j.eclinm.2022.101771 https://linkinghub.elsevier.com/retrieve/pii/S2589537022005004 https://linkinghub.elsevier.com/retrieve/pii/S2589537022005004

MOSA A S M , HOSSAIN A M , LAVOIE B J , et al . Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review [J ] . Front Pharmacol , 2020 , 11 : 329 . DOI: 10.3389/fphar.2020.00329 http://doi.org/10.3389/fphar.2020.00329

CROWDER S L , HOOGLAND A I , WELNIAK T L , et al . Metagenomics and chemotherapy-induced nausea: a roadmap for future research [J ] . Cancer , 2022 , 128 ( 3 ): 461 - 470 . DOI: 10.1002/cncr.v128.3 http://doi.org/10.1002/cncr.v128.3 https://acsjournals.onlinelibrary.wiley.com/toc/10970142/128/3 https://acsjournals.onlinelibrary.wiley.com/toc/10970142/128/3

JIN Y L , LI X R , JIANG C H , et al . An update in our understanding of the relationships between gene polymorphisms and chemotherapy-induced nausea and vomiting [J ] . Int J Gen Med , 2021 , 14 : 5879 - 5892 . DOI: 10.2147/IJGM.S329257 http://doi.org/10.2147/IJGM.S329257

HU Z H , LIANG W H , YANG Y P , et al . Personalized estimate of chemotherapy-induced nausea and vomiting: development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemotherapy [J ] . Medicine , 2016 , 95 ( 2 ): e2476 . DOI: 10.1097/MD.0000000000002476 http://doi.org/10.1097/MD.0000000000002476 https://journals.lww.com/00005792-201601120-00058 https://journals.lww.com/00005792-201601120-00058

AAPRO M , CAPRARIU Z , CHILINGIROV P , et al . Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea/emesis registry in oncology (NERO) [J ] . Eur J Cancer , 2022 , 166 : 126 - 133 . DOI: 10.1016/j.ejca.2022.01.028 http://doi.org/10.1016/j.ejca.2022.01.028

RADHAKRISHNAN V , PAI V , RAJARAMAN S , et al . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: an open-label, randomized phase 3 trial [J ] . Pediatr Blood Cancer , 2020 , 67 ( 9 ): e28532 . DOI: 10.1002/pbc.v67.9 http://doi.org/10.1002/pbc.v67.9 https://onlinelibrary.wiley.com/toc/15455017/67/9 https://onlinelibrary.wiley.com/toc/15455017/67/9

HESKETH P J , GRUNBERG S M , GRALLA R J , et al . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the aprepitant protocol 052 study group [J ] . J Clin Oncol , 2003 , 21 ( 22 ): 4112 - 4119 . DOI: 10.1200/JCO.2003.01.095 http://doi.org/10.1200/JCO.2003.01.095

SCHWARTZBERG L , BARBOUR S Y , MORROW G R , et al . Pooled analysis of phase Ⅲ clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) [J ] . Support Care Cancer , 2014 , 22 ( 2 ): 469 - 477 . DOI: 10.1007/s00520-013-1999-9 http://doi.org/10.1007/s00520-013-1999-9 http://link.springer.com/10.1007/s00520-013-1999-9 http://link.springer.com/10.1007/s00520-013-1999-9

NAVARI R M , NAGY C K , GRAY S E . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy [J ] . Support Care Cancer , 2013 , 21 ( 6 ): 1655 - 1663 . DOI: 10.1007/s00520-012-1710-6 http://doi.org/10.1007/s00520-012-1710-6

GRUNBERG S , CHUA D , MARU A , et al . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE [J ] . J Clin Oncol , 2011 , 29 ( 11 ): 1495 - 1501 . DOI: 10.1200/JCO.2010.31.7859 http://doi.org/10.1200/JCO.2010.31.7859

KIM H K , HSIEH R , CHAN A , et al . Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice [J ] . Support Care Cancer , 2015 , 23 ( 1 ): 293 - 300 . DOI: 10.1007/s00520-014-2376-z http://doi.org/10.1007/s00520-014-2376-z http://link.springer.com/10.1007/s00520-014-2376-z http://link.springer.com/10.1007/s00520-014-2376-z

National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) [EB/OL ] . 2017 , Version 5.0. ( 2017-11-27 )[ 2023-09-22 ] . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

DRANITSARIS G , MOLASSIOTIS A , CLEMONS M , et al . The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting [J ] . Ann Oncol , 2017 , 28 ( 6 ): 1260 - 1267 . DOI: 10.1093/annonc/mdx100 http://doi.org/10.1093/annonc/mdx100

MASCC/ESMO . MASCC/ESMO antiemetic guideline 2016 with updates in 2019 [EB/OL ] . 2019 . ( 2019-09-29 )[ 2023-09-22 ] . https://mascc.memberclicks.net/assets/Guidelines-Tools/Antiemetics/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf https://mascc.memberclicks.net/assets/Guidelines-Tools/Antiemetics/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf https://mascc.memberclicks.net/assets/Guidelines-Tools/Antiemetics/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf.

HUNTER J J , MAUNDER R G , SUI D W , et al . A randomized trial of nurse-administered behavioral interventions to manage anticipatory nausea and vomiting in chemotherapy [J ] . Cancer Med , 2020 , 9 ( 5 ): 1733 - 1740 . DOI: 10.1002/cam4.v9.5 http://doi.org/10.1002/cam4.v9.5 https://onlinelibrary.wiley.com/toc/20457634/9/5 https://onlinelibrary.wiley.com/toc/20457634/9/5

JAMES A , NAIR M M , ABRAHAM D S , et al . Effect of lorazepam in reducing psychological distress and anticipatory nausea and vomiting in patients undergoing chemotherapy [J ] . J Pharmacol Pharmacother , 2017 , 8 ( 3 ): 112 - 115 . DOI: 10.4103/jpp.JPP_54_17 http://doi.org/10.4103/jpp.JPP_54_17

HESKETH P J , KRIS M G , BASCH E , et al . Antiemetics: American Society of Clinical Oncology clinical practice guideline update [J ] . J Clin Oncol , 2017 , 35 ( 28 ): 3240 - 3261 . DOI: 10.1200/JCO.2017.74.4789 http://doi.org/10.1200/JCO.2017.74.4789

FEYER P C , MARANZANO E , MOLASSIOTIS A , et al . Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009 [J ] . Support Care Cancer , 2011 , 19 ( Suppl 1 ): S5 - S14 .

Radiation-induced emesis: a prospective observational multicenter Italian trial . The Italian Group for Antiemetic Research in Radiotherapy [J ] . Int J Radiat Oncol Biol Phys , 1999 , 44 ( 3 ): 619 - 625 . DOI: 10.1016/S0360-3016(99)00055-3 http://doi.org/10.1016/S0360-3016(99)00055-3 https://linkinghub.elsevier.com/retrieve/pii/S0360301699000553 https://linkinghub.elsevier.com/retrieve/pii/S0360301699000553

MARANZANO E , ANGELIS V D , PERGOLIZZI S , et al . A prospective observational trial on emesis in radiotherapy: analysis of 1 020 patients recruited in 45 Italian Radiation Oncology Centres [J ] . Radiother Oncol , 2010 , 94 ( 1 ): 36 - 41 . DOI: 10.1016/j.radonc.2009.11.001 http://doi.org/10.1016/j.radonc.2009.11.001 https://linkinghub.elsevier.com/retrieve/pii/S0167814009006136 https://linkinghub.elsevier.com/retrieve/pii/S0167814009006136

RUHLMANN C H , JAHN F , JORDAN K , et al . 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting [J ] . Support Care Cancer , 2017 , 25 ( 1 ): 309 - 316 . DOI: 10.1007/s00520-016-3407-8 http://doi.org/10.1007/s00520-016-3407-8 http://link.springer.com/10.1007/s00520-016-3407-8 http://link.springer.com/10.1007/s00520-016-3407-8

SALVO N , DOBLE B , KHAN L , et al . Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials [J ] . Int J Radiat Oncol Biol Phys , 2012 , 82 ( 1 ): 408 - 417 . DOI: 10.1016/j.ijrobp.2010.08.060 http://doi.org/10.1016/j.ijrobp.2010.08.060 https://linkinghub.elsevier.com/retrieve/pii/S0360301610032670 https://linkinghub.elsevier.com/retrieve/pii/S0360301610032670

AASS N , HÅTUN D E , THORESEN M , et al . Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage Ⅰ: a randomised, open trial in 23 patients [J ] . Radiother Oncol , 1997 , 45 ( 2 ): 125 - 128 . DOI: 10.1016/S0167-8140(97)00099-6 http://doi.org/10.1016/S0167-8140(97)00099-6 https://linkinghub.elsevier.com/retrieve/pii/S0167814097000996 https://linkinghub.elsevier.com/retrieve/pii/S0167814097000996

BEY P , WILKINSON P M , RESBEUT M , et al . A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients [J ] . Support Care Cancer , 1996 , 4 ( 5 ): 378 - 383 . DOI: 10.1007/BF01788845 http://doi.org/10.1007/BF01788845

FRANZÉN L , NYMAN J , HAGBERG H , et al . A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy [J ] . Ann Oncol , 1996 , 7 ( 6 ): 587 - 592 .

LANCIANO R , SHERMAN D M , MICHALSKI J , et al . The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy [J ] . Cancer Invest , 2001 , 19 ( 8 ): 763 - 772 .

PRIESTMAN T J , ROBERTS J T , LUCRAFT H , et al . Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation [J ] . Clin Oncol , 1990 , 2 ( 2 ): 71 - 75 . DOI: 10.1016/S0936-6555(05)80790-3 http://doi.org/10.1016/S0936-6555(05)80790-3 https://linkinghub.elsevier.com/retrieve/pii/S0936655505807903 https://linkinghub.elsevier.com/retrieve/pii/S0936655505807903

PRIESTMAN T J , ROBERTS J T , UPADHYAYA B K . A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy [J ] . Clin Oncol (R Coll Radiol) , 1993 , 5 ( 6 ): 358 - 363 . DOI: 10.1016/S0936-6555(05)80086-X http://doi.org/10.1016/S0936-6555(05)80086-X https://linkinghub.elsevier.com/retrieve/pii/S093665550580086X https://linkinghub.elsevier.com/retrieve/pii/S093665550580086X

KIRKBRIDE P , BEZJAK A , PATER J , et al . Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase Ⅲ study [J ] . J Clin Oncol , 2000 , 18 ( 9 ): 1960 - 1966 . DOI: 10.1200/JCO.2000.18.9.1960 http://doi.org/10.1200/JCO.2000.18.9.1960 https://ascopubs.org/doi/10.1200/JCO.2000.18.9.1960 https://ascopubs.org/doi/10.1200/JCO.2000.18.9.1960

National Cancer Institute of Canada Clinical Trials Group , WONG R K S , PAUL N , et al . 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19) [J ] . J Clin Oncol , 2006 , 24 ( 21 ): 3458 - 3464 .

JAHN F , RIESNER A , JAHN P , et al . Addition of the neurokinin-1-receptor antagonist (RA) aprepitant to a 5-hydroxytryptamine-RA and dexamethasone in the prophylaxis of nausea and vomiting due to radiation therapy with concomitant cisplatin [J ] . Int J Radiat Oncol Biol Phys , 2015 , 92 ( 5 ): 1101 - 1107 . DOI: 10.1016/j.ijrobp.2015.04.037 http://doi.org/10.1016/j.ijrobp.2015.04.037 https://linkinghub.elsevier.com/retrieve/pii/S0360301615004411 https://linkinghub.elsevier.com/retrieve/pii/S0360301615004411

RUHLMANN C H , CHRISTENSEN T B , DOHN L H , et al . Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial [J ] . Lancet Oncol , 2016 , 17 ( 4 ): 509 - 518 . DOI: S1470-2045(15)00615-4 http://doi.org/S1470-2045(15)00615-4

崔明 , 欧志莲 , 詹剑玲 . 肿瘤靶向药物不良反应发生率的meta分析 [J ] . 中国药物经济学 , 2021 , 16 ( 3 ): 50 - 54 .

CUI M , OU Z L , ZHAN J L . Meta-analysis of the incidence of adverse reactions to tumor-targeted drugs [J ] . China J Pharm Econ , 2021 , 16 ( 3 ): 50 - 54 .

ZHOU X X , YAO Z R , BAI H , et al . Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis [J ] . Lancet Oncol , 2021 , 22 ( 9 ): 1265 - 1274 . DOI: 10.1016/S1470-2045(21)00333-8 http://doi.org/10.1016/S1470-2045(21)00333-8

BONIFANT C L , JACKSON H J , BRENTJENS R J , et al . Toxicity and management in CAR T-cell therapy [J ] . Mol Ther Oncolytics , 2016 , 3 : 16011 . DOI: 10.1038/mto.2016.11 http://doi.org/10.1038/mto.2016.11 https://linkinghub.elsevier.com/retrieve/pii/S2372770516300353 https://linkinghub.elsevier.com/retrieve/pii/S2372770516300353

DAVILA M L , RIVIERE I , WANG X Y , et al . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia [J ] . Sci Transl Med , 2014 , 6 ( 224 ): 224ra25 .

KALFEIST L , GALLAND L , LEDYS F , et al . Impact of glucocorticoid use in oncology in the immunotherapy era [J ] . Cells , 2022 , 11 ( 5 ): 770 . DOI: 10.3390/cells11050770 http://doi.org/10.3390/cells11050770 https://www.mdpi.com/2073-4409/11/5/770 https://www.mdpi.com/2073-4409/11/5/770

CELIO L , CORTINOVIS D , COGONI A A , et al . Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study) [J ] . Sci Rep , 2023 , 13 ( 1 ): 1257 . DOI: 10.1038/s41598-023-28464-9 http://doi.org/10.1038/s41598-023-28464-9

KOSAKA Y , TANINO H , SENGOKU N , et al . Phase Ⅱ randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy [J ] . Support Care Cancer , 2016 , 24 ( 3 ): 1405 - 1411 . DOI: 10.1007/s00520-015-2905-4 http://doi.org/10.1007/s00520-015-2905-4 http://link.springer.com/10.1007/s00520-015-2905-4 http://link.springer.com/10.1007/s00520-015-2905-4

ITO Y , TSUDA T , MINATOGAWA H , et al . Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy [J ] . J Clin Oncol , 2018 , 36 ( 10 ): 1000 - 1006 . DOI: 10.1200/JCO.2017.74.4375 http://doi.org/10.1200/JCO.2017.74.4375 https://ascopubs.org/doi/10.1200/JCO.2017.74.4375 https://ascopubs.org/doi/10.1200/JCO.2017.74.4375

CELIO L , CORTINOVIS D , COGONI A A , et al . Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study [J ] . BMC Cancer , 2022 , 22 ( 1 ): 915 . DOI: 10.1186/s12885-022-10018-3 http://doi.org/10.1186/s12885-022-10018-3

CHENG Y , WU Z H , SHI L S , et al . Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: a randomized, open-label, phase 3 trial [J ] . EClinicalMedicine , 2022 , 49 : 101480 . DOI: 10.1016/j.eclinm.2022.101480 http://doi.org/10.1016/j.eclinm.2022.101480 https://linkinghub.elsevier.com/retrieve/pii/S2589537022002103 https://linkinghub.elsevier.com/retrieve/pii/S2589537022002103

马紫妍 , 陈芳芳 , 程茜茜 , 等 . 灸法防治肿瘤放化疗后恶心呕吐的meta分析 [J ] . 中国中医药现代远程教育 , 2021 , 19 ( 17 ): 58 - 62 .

MA Z Y , CHEN F F , CHENG X X , et al . Meta-analysis of moxibustion in the prevention and treatment of nausea and vomiting after radiotherapy and chemotherapy of tumors [J ] . Chin Med Mod Distance Educ China , 2021 , 19 ( 17 ): 58 - 62 .

邹吉轩 , 孙妍 , 宋英 , 等 . 针刺防治化疗引起急性和延迟性呕吐的meta分析 [J ] . 世界中医药 , 2021 , 16 ( 18 ): 2735 - 2741 .

ZOU J X , SUN Y , SONG Y , et al . Meta-analysis of acupuncture prevention and treatment of acute and delayed vomiting caused by chemotherapy [J ] . World Chin Med , 2021 , 16 ( 18 ): 2735 - 2741 .

CHEN L C , WU X H , CHEN X S , et al . Efficacy of auricular acupressure in prevention and treatment of chemotherapy-induced nausea and vomiting in patients with cancer: a systematic review and meta-analysis [J ] . Evid Based Complement Alternat Med , 2021 , 2021 : 8868720 .

TAN J Y , MOLASSIOTIS A , SUEN L K P , et al . Effects of auricular acupressure on chemotherapy-induced nausea and vomiting in breast cancer patients: a preliminary randomized controlled trial [J ] . BMC Complement Med Ther , 2022 , 22 ( 1 ): 87 . DOI: 10.1186/s12906-022-03543-y http://doi.org/10.1186/s12906-022-03543-y

刘述梅 , 许玲 , 周益凡 , 等 . 小半夏汤加味治疗NSCLC化疗所致恶心呕吐的临床研究 [J ] . 新疆中医药 , 2019 , 37 ( 1 ): 17 - 19 .

LIU S M , XU L , ZHOU Y F , et al . Clinical study of modified XiaoBanXia Decoction in treating nausea and vomiting caused by NSCLC chemotherapy [J ] . Xinjiang J Tradit Chin Med , 2019 , 37 ( 1 ): 17 - 19 .

陶文婷 , 许培箴 , 沈建峰 , 等 . 小半夏汤协同防治妇科肿瘤化疗性恶心呕吐临床研究 [J ] . 现代中医药 , 2021 , 41 ( 5 ): 76 - 80 .

TAO W T , XU P Z , SHEN J F , et al . Clinical study of xiaobanxia decoction in the prevention and treatment of chemotherapy-induced nausea and vomiting in gynecological tumors [J ] . Mod Tradit Chin Med , 2021 , 41 ( 5 ): 76 - 80 .

崔艺馨 , 米继伟 , 唐潇然 , 等 . 小半夏汤联合穴位针刺治疗乳腺癌术后化疗相关性恶心呕吐的临床研究 [J ] . 中国医药 , 2021 , 16 ( 8 ): 1231 - 1235 .

CUI Y X , MI J W , TANG X R , et al . Clinical study of Xiaobanxia Decoction combined with acupuncture at acupoint on the treatment of chemotherapy-induced nausea and vomiting after breast cancer surgery [J ] . China Med , 2021 , 16 ( 8 ): 1231 - 1235 .

王晋秋 , 陈海燕 , 翟长云 . 香砂六君子汤加味治疗化疗后迟发性恶心呕吐的临床研究 [J ] . 世界最新医学信息文摘 , 2018 , 18 ( 49 ): 25 - 26 .

WANG J Q , CHEN H Y , ZHAI C Y . Clinical study on delayed nausea and vomiting after chemotherapy with Xiangsha Liujunzi Decoction [J ] . World Latest Med Inf , 2018 , 18 ( 49 ): 25 - 26 .

HARADA T , AMANO T , IKARI T , et al . Rikkunshito for preventing chemotherapy-induced nausea and vomiting in lung cancer patients: results from 2 prospective, randomized phase 2 trials [J ] . Front Pharmacol , 2017 , 8 : 972 . DOI: 10.3389/fphar.2017.00972 http://doi.org/10.3389/fphar.2017.00972

LU C X , CHEN X W , YAN X C , et al . The preventive and relieving effects of ginger on postoperative nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials [J ] . Int J Nurs Stud , 2022 , 125 : 104094 . DOI: 10.1016/j.ijnurstu.2021.104094 http://doi.org/10.1016/j.ijnurstu.2021.104094 https://linkinghub.elsevier.com/retrieve/pii/S0020748921002418 https://linkinghub.elsevier.com/retrieve/pii/S0020748921002418

CHANG W P , PENG Y X . Does the oral administration of ginger reduce chemotherapy-induced nausea and vomiting: a meta-analysis of 10 randomized controlled trials [J ] . Cancer Nurs , 2019 , 42 ( 6 ): E14 - E23 . DOI: 10.1097/NCC.0000000000000648 http://doi.org/10.1097/NCC.0000000000000648 https://journals.lww.com/10.1097/NCC.0000000000000648 https://journals.lww.com/10.1097/NCC.0000000000000648

Views

1533

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)

Current status and future perspectives on consensus and controversies in advanced breast cancer for 2024

Important research progress in clinical practice for early breast cancer in 2024

Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)

Related Author

Association Committee of Rehabilitation and Palliative Care China Anti-Cancer

Association Committee of Cancer Pain Fujian Anti-Cancer

Yongmei YIN

Hongxia WANG

Xichun HU

Tao WANG

Xiaobo WANG

Feng JIN

Related Institution

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association

Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital

Department of Breast Surgery, the First Affiliated Hospital of China Medical University

Head and Neck Cancer Committee of Chinese Society of Clinical Oncology

Head and Neck Cancer Committee of Chinese Anti-Cancer Association

AI问答

⁰